Paxman AB (publ) (PAX.ST)
SEK 71.8
(0.84%)
SEK 71.8
(0.84%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.53 Million SEK | -40.52% |
| 2022 | 4.25 Million SEK | -26.93% |
| 2021 | 5.82 Million SEK | -64.5% |
| 2020 | 16.41 Million SEK | 16.34% |
| 2019 | 14.1 Million SEK | 3219.53% |
| 2018 | 425 Thousand SEK | 83.19% |
| 2017 | 232 Thousand SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 2.35 Million SEK | -6.83% |
| 2024 Q2 | 1.87 Million SEK | -20.35% |
| 2023 Q4 | 2.53 Million SEK | -18.27% |
| 2023 Q3 | 3.09 Million SEK | -15.86% |
| 2023 FY | 2.53 Million SEK | -40.52% |
| 2023 Q1 | 3.88 Million SEK | -8.69% |
| 2023 Q2 | 3.68 Million SEK | -5.27% |
| 2022 Q3 | 4.63 Million SEK | -8.62% |
| 2022 FY | 4.25 Million SEK | -26.93% |
| 2022 Q1 | 5.39 Million SEK | -7.4% |
| 2022 Q4 | 4.25 Million SEK | -8.1% |
| 2022 Q2 | 5.06 Million SEK | -6.04% |
| 2021 Q3 | 25.5 Million SEK | -5.15% |
| 2021 Q4 | 5.82 Million SEK | -77.15% |
| 2021 FY | 5.82 Million SEK | -64.5% |
| 2021 Q1 | 27.5 Million SEK | 67.56% |
| 2021 Q2 | 26.88 Million SEK | -2.24% |
| 2020 FY | 16.41 Million SEK | 16.34% |
| 2020 Q3 | 17.91 Million SEK | -18.19% |
| 2020 Q4 | 16.41 Million SEK | -8.37% |
| 2020 Q2 | 21.89 Million SEK | 57.28% |
| 2020 Q1 | 13.92 Million SEK | -1.32% |
| 2019 Q4 | 14.1 Million SEK | 34.59% |
| 2019 Q3 | 10.48 Million SEK | 90.48% |
| 2019 Q1 | 548 Thousand SEK | 28.94% |
| 2019 FY | 14.1 Million SEK | 3219.53% |
| 2019 Q2 | 5.5 Million SEK | 904.2% |
| 2018 Q3 | 591 Thousand SEK | 86.44% |
| 2018 FY | 425 Thousand SEK | 83.19% |
| 2018 Q1 | 339 Thousand SEK | 46.12% |
| 2018 Q4 | 425 Thousand SEK | -28.09% |
| 2018 Q2 | 317 Thousand SEK | -6.49% |
| 2017 FY | 232 Thousand SEK | 0.0% |
| 2017 Q2 | 2.65 Million SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | 232 Thousand SEK | -93.17% |
| 2017 Q3 | 3.39 Million SEK | 27.92% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.826% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.826% |
| Arcoma AB | 1.92 Million SEK | -31.396% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 94.015% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.856% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 95.612% |
| CellaVision AB (publ) | 28.66 Million SEK | 91.167% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -1035.426% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -44.438% |
| Duearity AB (publ) | 2.94 Million SEK | 13.878% |
| Dignitana AB (publ) | 6.07 Million SEK | 58.335% |
| Episurf Medical AB (publ) | 2.3 Million SEK | -10.087% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.935% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 60.144% |
| Iconovo AB (publ) | 4.9 Million SEK | 48.399% |
| Integrum AB (publ) | 4.84 Million SEK | 47.735% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -1128.983% |
| Mentice AB (publ) | 2.14 Million SEK | -18.097% |
| OssDsign AB (publ) | 214 Thousand SEK | -1083.178% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | 15.712% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 39.411% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 86.815% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -150.198% |
| Senzime AB (publ) | 8.57 Million SEK | 70.483% |
| SpectraCure AB (publ) | 4.39 Million SEK | 42.415% |
| Stille AB | 38.06 Million SEK | 93.348% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.865% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 88.039% |